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Abstract
Introduction
The main risk factors for head and neck squamous cell carcinoma (HNSCC) are tobacco
and alcohol consumption and human papillomavirus (HPV) infection. However, in a subset
of patients, no risk factors can be identified. Glutathione S-transferase π (GTSP1) is a car-
cinogen-detoxifying enzyme that is activated by exposure to carcinogens, and it is associ-
ated with a reduction in response to toxic therapies. We studied the expression of GTSP1 in
tumor and non-tumor tissue samples from patients with and without these risks to identify
whether GTSP1 expression differs according to exposure to carcinogens.
Materials and methods
Non-smoker/non-drinker (NSND) and smoker/drinker (SD) patients were matched accord-
ing to age, gender, tumor site, TNM stage, grade and histological variants to establish 47
pairs of patients who have been previously tested for HPV. GTSP1 immunostaining was
analyzed using a semi-quantitative method with scores ranging from 0 to 3 according to the
area of immunostaining.
Results
GTSP1 expression was detected in the tumors of both groups. GTSP1 expression was
higher in the non-tumor margins of SD patients (p = 0.004). There was no association
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between GTSP1 expression and positivity for HPV. No differences in survival were
observed according to GTSP1 staining in tumors and non-tumor margins.
Conclusion
This study showed that GTSP1 was expressed in tumors of HNSCC patients regardless of
smoking, drinking or HPV infection status. The difference in GTSP1 expression in non-
tumor margins between the two groups may have been due to two possible reasons. First,
elevated GTSP1 expression in SD patients might be the result of activation of GTSP1 in
response to exposure to carcinogens. Second, alternatively, impairment in the detoxifying
system of GTSP1, as observed by the reduced expression of GTSP1, might make patients
susceptible to carcinogens other than tobacco and alcohol, which may be the underlying
mechanism of carcinogenesis in the absence of risk factors.
Introduction
Head and neck squamous cell carcinoma (HNSCC) is a major health problem worldwide.
Tobacco and alcohol are the main risk factors of HNSCC in addition to human papillomavirus
(HPV) infection [1]. However, in a small but increasing subset of patients, no risk factors can
be identified, indicating a possible role of environmental and/or genetic factors in cancer
development.
Recent studies [2–4] have demonstrated that genetic polymorphisms that impair the activ-
ity of detoxifying enzymes might contribute to carcinogenesis. One of the main systems of cel-
lular detoxifying enzymes consists of glutathione S-transferases (GSTs), a superfamily of phase
II enzymes that participate in the detoxification of carcinogens, including tobacco and alcohol
[5–9].
Glutathione S-transferases π (GTSP1) is one of the GSTs that are usually expressed in
HNSCC [10]. It has also been implicated in resistance to cytotoxic treatment modalities in can-
cer [11, 12], as it detoxifies chemotherapeutic compounds and products of oxidative stress gen-
erated by radiotherapy [13–15]. Low expression of GTSP1 may be associated with better
treatment responses and better prognosis [16].
It is unknown whether an increase in expression of GTSP1 in HNSCC is a consequence
of persistent exposure to tobacco and alcohol, which is frequently observed in patients with
HNSCC, or whether GTSP1 is activated by other carcinogenic mechanisms in these tumors.
This can impact the use of GTSP1 as a possible predictor of treatment response and prognostic
marker in HNSCC patients who are not exposed to alcohol and tobacco. Prediction of disease
response and prognosis should be differentially evaluated according to the smoking and drink-
ing habits of patients [17]. However, no study on GTSP1 has been conducted specifically in
non-smoker/non-drinker (NSND) patients. These data could also clarify whether the impair-
ment of the detoxifying effect of GTSP1 could be one of the mechanisms underlying the inci-
dence of HNSCC in NSND patients. Thus, the aim of this study was to compare the expression
of GTSP1 in tumor and non-tumor tissue samples from patients with HNSCC according to
their smoking and drinking habits. We also analyzed the prognostic value of GTSP1 expres-
sion in patients who were exposed to tobacco or alcohol, since both these habits are important
predictors of survival and can act as confounders in the analysis of the prognostic value of
GTSP1. Additionally, our group of smoker/drinker (SD) patients were matched to a selected
subset of NSND patients and are thus not representative of all SD patients.
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Materials and methods
Patients older than 18 years with squamous cell carcinoma of the oral cavity (lips excluded),
oropharynx, larynx and hypopharynx without previous treatment were prospectively enrolled
from January 2001 to February 2009 in the head and neck surgery departments of five hospitals
of the Brazilian Head and Neck Genome Project, Gencapo, a collaborative consortium of
research groups from hospitals and universities in the state of São Paulo, Brazil.
Ethics statement
All clinical investigations were conducted according to the principles in the Declaration of
Helsinki. Written informed consent was obtained from each participant during study enroll-
ment. The study was approved by the Ethics Committee of the Hospital das Clinicas, Univer-
sity of São Paulo under the protocol number 0511/07. All materials provided to the research
team were de-identified.
Among the 1633 patients included, 80 were considered NSND [18]. Patients were consid-
ered to be smokers if they had smoked at least one cigarette, cigar, or pipe daily for at least one
year during their lifetime and as drinkers if they had consumed alcoholic beverages at least
once a month on a regular basis [19]. SD patients were selected as matched pairs of NSND
patients according to gender, age (+/- 5 years) tumor site, clinical stage, tumor degree and his-
tological variants. Tumor staging was performed according to the 5th (until 2002) and 6th edi-
tions (since 2003) of the American Joint Committee on Cancer (AJCC) TNM classification
criteria [20, 21].
Formalin-fixed, paraffin-embedded (FFPE) samples were obtained from all NSND patients
and corresponding SD pairs, which included both tumors and non-tumor margins, to evaluate
GTSP1 expression via immunohistochemistry (IHC).
Previous data on HPV were also retrieved for the patients using PCR [22] and analyzed
according to GTSP1 expression in both SD and NSND patient groups.
Immunohistochemical assay
Consecutive 3 μm-thick sections were cut from each paraffin block and mounted οn glass
slides pre-treated with 3-aminopropyl triethoxysilane/acetone solution. Following deparaffini-
zation, the sections were re-hydrated, treated with citrate buffer at 96˚C for 30 min and further
treated with 3% H2O2 in methanol (v/v) for 30 min to block endogenous peroxidases. To
block non-specific binding, the slides were treated with Background Sniper from Starr Trek
Detection kit (Biocare, California, USA) for 10 min. The sections were then incubated for 16
hours at 4˚C with the specific antibody Novocastra NCL-L-GTSP1-437 (Leica Biosytems, UK).
The slides were incubated with biotinylated secondary antibody and then with streptavidin-
biotin peroxidase following the manufacturer’s instructions (Kit Starr Trek Detection, Biocare,
California, USA). The immunostain was visualized with 3,3’-diaminobenzidine tetrahy-
drochloride (DAB) containing 0.005% H2O2 and counterstained with hematoxylin. Negative
controls were established by replacing the primary antibody with buffer. The slides were ana-
lyzed using light microscopy (400× magnification).
Negative controls were used in all steps. Tissue samples known to be positive for GTSP1
were used as positive controls.
Two of the authors (POS and PMC), who were blinded to the clinical data, quantified
GTSP1 expression in the entire area of each sample in a semi-quantitative fashion. The expres-
sion was ranked as follows: 0 in case of absence of staining or staining in less than 10% of cells;
1 for staining in 10% to 30% of cells; 2 for staining in 31% to 60% of cells; and 3 for staining in
GSTP1 in head and neck cancer in non smoker and non drinker patients
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more than 60% of cells [23]. The categories were further merged into low (0 and 1) and high (2
and 3) GTSP1 expression to facilitate statistical analyses [24].
Statistical analysis
Fisher’s exact test was used to test the association between HPV and GTSP1 for all patients.
The data on non-tumoral and tumoral GTSP1 expression and HPV positivity among pairs
were analyzed using McNemar’s test. Overall survival was analyzed only for NSND patients.
Survival was determined from the end of treatment until death or loss of follow-up and ana-
lyzed using Kaplan-Meier curves and the log-rank test.
A two-tailed p-value of 0.05 was considered significant. No adjustments for multiple com-
parisons were made since the exploratory nature of the study. Statistical analyses were per-
formed on SPSS for Windows v. 18.
Results
Among the 80 NSND patients, it was possible to find matched SD patient counterparts for 47.
In the 47 matched pairs, there were 47 NSND and 37 SD patients. For this reason, some SD
patients were matched to more than one NSND patient based on the principle of hot deck
imputation [25]. Table 1 displays the clinical features of the paired samples. Most of the
patients were female (62%) and presented with oral cavity tumors.
Table 1. Clinical features of the paired samples.
Feature NSND SD
N = 47 N = 47
N (%) N (%)
Age
Median (range) 65 (35–83) 68 (39–80)
Site
Oral cavity 33 (70.2) 33 (70.2)
Oral cavity + oropharynx 2 (4.3) 2 (4.3)
Oropharynx 1 (2.1) 1 (2.1)
Larynx 10 (21.3) 10 (21.3)
Hypopharynx 1 (2.1) 1 (2.1)
T stage
T1 10 (21.3) 16 (34.0)
T2 18 (32.3) 10 (21.3)
T3 6 (12.8) 4 (8.5)
T4 13 (27.7) 17 (36.2)
N stage
N0 29 (61.7) 29 (61.7)
N+ 18 (38.3) 18 (38.3)
Differentiation
Well differentiated 28 (62.2) 22 (46.8)
Moderately differentiated 16 (35.6) 24 (51.1)
Poorly differentiated 1 (2.2) 1 (2.1)
Tumor variants
Squamous cell carcinoma 41 (97.6) 42 (91.3)
Verrucous carcinoma 0
Basaloid 1 (2.4) 4 (8.7)
NSND: Non-smoker/non-drinker; SD: smoker/drinker
https://doi.org/10.1371/journal.pone.0182600.t001
GSTP1 in head and neck cancer in non smoker and non drinker patients
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It was possible to perform successful GTSP1 immunostaining for tumor samples from 30
pairs of patients and for non-tumor samples from 16 pairs of patients. No histological features
of pre-malignant lesions were detected in any of the non-tumor margins.
Fig 1 represents the examples of different GTSP1 expression patterns in tumor and non-
tumor samples. Table 2 presents the data on GTSP1 expression according to smoking and
drinking habits. No differences were observed for the expression of GTSP1 in tumors between
SD and NSND patients. An increase in the expression of GTSP1 was observed in the non-
tumor margins of SD patients (p = 0.004).
No differences were observed for HPV positivity between NSND and SD patients. In addi-
tion, we found no association between HPV positivity and expression of GTSP1 among NSND
patients or among SD patients [S1–S5 Tables].
There were no significant differences between the survival of NSND patients with high or
low GTSP1 expression in either tumor or non-tumor margins (Fig 2A and 2B), even though
the survival curves shown in Fig 2B seemed very different (Fig 2B).pression might have jeopar-
dized the detection of a difference in survival according to GSTPI expressiogin
Original data are provided as supporting information (S6 and S7 Tables).
Discussion
This is the first study to analyze the expression of GTSP1 in NSND patients with HNSCC. We
detected GTSP1 expression in both tumors and non-tumor margins of patients with HNSCC
Fig 1. Expression of GTSP1 via immunohistochemistry. A: High expression of GTSP1 in non-tumor margin; B: low expression of GTSP1 in non-tumor
margin; C: high expression of GTSP1 in tumor.
https://doi.org/10.1371/journal.pone.0182600.g001
Table 2. GTSP1 expression according to smoking and drinking habits. A: GSTP1 expression in non-tumor margins; B: GSTP1 expression in tumor.
A
GTSP1non-tumor margin SD low SD high total p¥
NSND low 1 (6.3%)§ 9 (56.3%)¶ 10 (62.5%) 0.004
NSND high 0¶ 6 (37.5%)§ 6 (37.5%)
B
GTSP1 tumor SD low SD high total p¥
NSND low 0§ 2 (6.7%)¶ 2 (6.7%) 1
NSND high 1 (3.3%) ¶ 27 (90.0%)§ 28 (93.3%)
¥McNemar’s test–each unit represents a pair of NSND and SD patients;
§concordant pairs (high-high or low-low)
¶discordant pairs (high-low or low-high)
https://doi.org/10.1371/journal.pone.0182600.t002
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irrespective of their drinking and smoking habits. However, GTSP1 expression was higher in
the non-tumor margins of SD patients, which reinforces the detoxifying role of GTSP1 and
indicates GTSP1 as a biomarker of exposure of non-neoplastic tissues to carcinogens.
The method of matched paired analysis enabled us to control for several possible confound-
ers and analyze the data from patients with comparable clinical features who were only distinct
in their exposure to carcinogens such as alcohol and tobacco. This information is not usually
reported in the literature, as smoking and drinking habits are the most prevalent risk factors
for HNSCC.
GTSP1 expression in the non-tumor margins was higher in the SD group compared to that
in the NSND group. However, we cannot infer whether the exposure of the mucosal tissues of
these patients to carcinogens was higher or lower than that of the mucosal tissues of healthy
individuals. These data can be interpreted in two possible ways: First, there may have been an
increase in GTSP1 expression in the mucosa of SD patients in response to the high degree of
exposure to carcinogens. Second, alternatively, the reduction in the expression of GTSP1 in
the mucosa of NSND patients could represent a risk factor for the development of cancer in
this subset of patients. The relationship among GTSP1 expression, carcinogenesis and smok-
ing and drinking habits is still unclear [8, 17, 26, 27], but we believe that our results reinforce
the hypothesis that the status of GTSP1 should be analyzed in addition to the information
regarding smoking and drinking habits in patients. Analysis of the genetic polymorphisms
Fig 2. Overall survival of NSND patients according to GTSP1 expression. A: GTSP1 expression in non-
tumor margins; B: GTSP1 expression in tumors.
https://doi.org/10.1371/journal.pone.0182600.g002
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and enzymatic function of GTSP1 in these patients as well as in healthy subjects may clarify
our findings. Polymorphisms in the GTSP1 gene have been associated with a reduction in the
detoxifying capacity of the enzyme [8, 9, 28–31]. GSTs are involved in the detoxification of sev-
eral drugs [32] and molecules related to oxidative stress; the generation of oxidative stress is an
important antineoplastic mechanism of radiotherapy. An increase in the expression of GSTs
might be partially responsible for resistance to chemotherapy in several tumors [11, 14, 24, 33,
34]. In contrast, genetic silencing of GTSP1 can increase the sensitivity of tumor cells to anti-
neoplastic drugs, suggesting that low GTSP1 expression might be related to increased survival
due to better response to treatment [16, 35]. Thus, GTSP1 might be not only a prognostic
marker but also a predictor of response to treatment, and GTSP1 levels may thus guide treat-
ment decisions. Studies on the prognostic value of GTSP1 in HNSCC have demonstrated
worse prognosis in patients with increased expression of GTSP1 in tumors. However, these
studies did not differentiate SD from NSND patients [9, 30, 36]. For this reason, we specifically
analyzed the overall survival of NSND patients according to GTSP1 expression. Although the
survival curves for patients with high and low tumoral expression of GTSP1 were visually dis-
tinct, the difference was not significant. This may have been because of the small number of
patients with low expression of GTSP1 and because of the low rate of mortality among these
patients.
The lack of association between HPV positivity and smoking and drinking habits might be
explained by the fact that HPV-related cancers are not very common in Brazil [37]. Indeed,
there is a geographical heterogeneity in HPV-related HNSCC worldwide [38]. Additionally,
patients were recruited from the departments of head and neck surgery at the hospitals partici-
pating in this study. HPV usually affects the oropharynx, and tumors in these sites are fre-
quently treated using non-surgical modalities with good response. In our study sample, most
patients had tumors of the oral cavity, where HPV plays a minor and still unclear role.
Limitations
The main limitation of our study was the small number of matched pairs, since HNSCC is less
common in NSND individuals. Additionally, several NSND patients were elderly females with
oral cavity tumors [18] who were difficult to match, because it is uncommon to find elderly
women who smoke and drink. This might have been responsible for an increase in type 2
errors in our analyses. Nevertheless, these difficulties reinforced the effectiveness of the pairing
method in controlling for confounders. A larger population size than that available from our
consortium with more than 1600 patients is necessary to increase the power of our analyses.
However, while challenging, the study on NSND patients is also a unique strength of this
study. Since we did not study healthy subjects, we could not demonstrate whether GTSP1 is
directly involved in the development of HNSCC. In this regard, this study primarily proposes
the hypothesis that the detoxification of carcinogens is likely disrupted in NSND patients.
Conclusion
Although studies investigating the polymorphisms in GTSP1 and other in vitro/in vivo studies
are necessary to confirm our hypothesis, we have identified that the metabolic disturbance of
carcinogen detoxification in NSND patients with HNSCC may be a possible risk factor for the
development of cancer in patients without known risk factors. Additionally, if the rationale for
the use of GTSP1 as a prognostic and predictive marker is further confirmed by other studies,
the results should be interpreted in light of the information on the smoking and drinking hab-
its of patients because these factors are directly related to GTSP1 expression, as demonstrated
by our data.
GSTP1 in head and neck cancer in non smoker and non drinker patients
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